(AOF) – Carmat today announces a software improvement to significantly strengthen the safety profile of its Aeson artificial heart. The medtech specifies that the software of this prosthesis will now be able to detect in real time the signals of possible malfunctions of the device. The software will then immediately adapt the control of the prosthesis so that its performance is not affected, and the protection of the patient is not impacted.
These changes, developed and tested internally, will first be deployed on all hearts currently implanted in patients, as part of a software update for which “safety information” is published. They will then be integrated into the production process of Aeson cores, after obtaining the appropriate regulatory authorizations.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.